Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy … (NCT00211445) | Clinical Trial Compass
CompletedPhase 2
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
United States11 participantsStarted 2002-07
Plain-language summary
Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The etiology is unknown, but according to the studies this condition is more common in young males and is associated with type A personality. Clinically, CSC is characterized by serous retinal detachment and area of leakage of in the subretinal space. The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, there is an indication for focal laser photocoagulation therapy of the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease of RPE thus rendering laser treatment ineffective.The purpose of this medical research study is to evaluate Verteporfin therapy as an approach which may benefit patients with CSC, based on observations in exudative type of AMD patients treated with Photodynamic Therapy using Verteporfin.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Evidence of chronic central serous chorioretinopathy and clinical/angiographic findings typical of the disease of greater than 6 months duration.Chronic central serous chorioretinopathy could be defined on the basis of two factors: a) persistence of the detachment for more than 6 months and b) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium.
. VA 20/40 and 20/320 Study Eye on the ETDRS visual acuity chart.
. VA 20/800 or better Fellow Eye on the ETDRS visual acuity chart.
Exclusion criteria
. Patient with tears in retinal pigment epithelium.
. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial used photodynamic therapy with a drug called verteporfin to treat chronic central serous chorioretinopathy — how does that approach compare to what's currently recommended for my specific situation, and is standard care still an option worth trying first?
2Since this was a Phase 2 trial that has already been completed, has my doctor seen its results, and what did the findings about vision changes over 24 months actually show for patients like me?
3The trial measured changes in visual acuity using something called ETDRS over two years — based on what this study found, how meaningful were those vision changes in real everyday terms, and how likely is it that I might see a similar benefit?
4Photodynamic therapy with verteporfin affects blood vessels in the eye — what are the known risks or side effects from this treatment that I should weigh against the potential for vision improvement?
5Since this trial is completed, are there newer or follow-up studies on photodynamic therapy for chronic central serous chorioretinopathy that my doctor thinks are more relevant to my case right now?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
mean change in VA (ETDRS) from baseline to 24 months
Timeframe: 24 months
2
investigate the potential of photodynamic therapy using verteporpin in chronic central serous chorioretinopathy